Highway To FIM – How To Avoid Roadblocks During Preclinical Development

Nuvisan Lunch & Learn

In early drug development, thorough understanding of drug metabolism and toxicology is essential for success. This knowledge helps us identify potential risks, design effective risk mitigation strategies, and accelerate the process of bringing safe and efficacious drugs to patients, improving their health and quality of life.

In this NUVISAN Lunch & Learn, our experts will share an overview and exclusive insight into the considerations and various tailor-made approaches to address these challenges during preclinical compound profiling and beyond.


10:00 – 10:30
Welcome Reception & Introduction
Dr. Stephanie Urschel (VP Business Development)
Dr. Alexander Aslanidis (Business Development Manager)
Dr. Michael Meyring (Head of PK Sciences)

10:30 – 11:10
Don’t let drug-drug-interactions be a blockade on your way to FIM
Dr. Dirk Scharn (Head of In Vitro PK)

11:10 – 11:50
Early human MetID – smooth the road to human mass balance
Dr. Matthias Bader (Head of Biotransformation)

12:00 – 13:00
Lunch sponsored by NUVISAN

13:10 – 13:50
Toxicology studies – how to get to FIM on the fast track
Dr. Burkhard Flick (Head of Toxicology)

13:50 – 15:00
Closing Remarks & QA

Tue, 21.11.2023 | 10:00 - 15:00

Aula am Campus der Universität Wien
Spitalgasse 2
1090 Vienna

Nuvisan Website with additional information